Terms: = Endocrine gland cancer AND CTCF, P49711, 10664, ENSG00000102974 AND Prognosis
4 results:
1. RPL35A drives ovarian cancer progression by promoting the binding of YY1 to ctcf promoter.
Wu H; Xia L; Sun L; Li D; Liu X; Song H; Sheng J; Wang K; Feng Q
J Cell Mol Med; 2024 Mar; 28(6):e18115. PubMed ID: 38436544
[TBL] [Abstract] [Full Text] [Related]
2. The ctcf/LncRNA-PACERR complex recruits E1A binding protein p300 to induce pro-tumour macrophages in pancreatic ductal adenocarcinoma via directly regulating PTGS2 expression.
Liu Y; Wang X; Zhu Y; Cao Y; Wang L; Li F; Zhang Y; Li Y; Zhang Z; Luo J; Deng X; Peng C; Wei G; Chen H; Shen B
Clin Transl Med; 2022 Feb; 12(2):e654. PubMed ID: 35184402
[TBL] [Abstract] [Full Text] [Related]
3.
Hillman JC; Pugacheva EM; Barger CJ; Sribenja S; Rosario S; Albahrani M; Truskinovsky AM; Stablewski A; Liu S; Loukinov DI; Zentner GE; Lobanenkov VV; Karpf AR; Higgins MJ
Mol Cancer Res; 2019 Oct; 17(10):2051-2062. PubMed ID: 31292201
[TBL] [Abstract] [Full Text] [Related]
4. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/ctcf expression ratio and advanced stage.
Woloszynska-Read A; Zhang W; Yu J; Link PA; Mhawech-Fauceglia P; Collamat G; Akers SN; Ostler KR; Godley LA; Odunsi K; Karpf AR
Clin Cancer Res; 2011 Apr; 17(8):2170-80. PubMed ID: 21296871
[TBL] [Abstract] [Full Text] [Related]
